Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

URGN

UroGen Pharma (URGN)

UroGen Pharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:URGN
DateTimeSourceHeadlineSymbolCompany
21/02/202500:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
21/02/202500:00Business WireUroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research CollaborationsNASDAQ:URGNUroGen Pharma Ltd
15/02/202506:30Business WireUroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102NASDAQ:URGNUroGen Pharma Ltd
13/02/202500:00Business WireData from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of UrologyNASDAQ:URGNUroGen Pharma Ltd
05/02/202503:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
05/02/202503:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
05/02/202503:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
31/01/202500:00Business WireUroGen Pharma to Present at Upcoming Investor ConferencesNASDAQ:URGNUroGen Pharma Ltd
23/01/202500:00Business WireNew Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)NASDAQ:URGNUroGen Pharma Ltd
16/01/202500:00Business WireENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025NASDAQ:URGNUroGen Pharma Ltd
14/01/202523:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
07/12/202400:00Business WireUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:URGNUroGen Pharma Ltd
06/12/202407:30Business WireLong-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®NASDAQ:URGNUroGen Pharma Ltd
06/12/202407:15Business WireUGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBCNASDAQ:URGNUroGen Pharma Ltd
03/12/202400:00Business WireUroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet NeedsNASDAQ:URGNUroGen Pharma Ltd
27/11/202400:00Business WireNew Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®NASDAQ:URGNUroGen Pharma Ltd
18/11/202422:16Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:URGNUroGen Pharma Ltd
07/11/202400:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:URGNUroGen Pharma Ltd
07/11/202400:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
07/11/202400:00Business WireUroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025NASDAQ:URGNUroGen Pharma Ltd
06/11/202400:00Business WireUroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation ConferenceNASDAQ:URGNUroGen Pharma Ltd
30/10/202423:00Business WireUroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024NASDAQ:URGNUroGen Pharma Ltd
28/10/202423:00Business WireENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBCNASDAQ:URGNUroGen Pharma Ltd
16/10/202407:30Business WireUroGen Announces FDA Acceptance of its New Drug Application for UGN-102NASDAQ:URGNUroGen Pharma Ltd
10/10/202407:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
10/10/202407:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
09/10/202423:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
09/10/202423:00Business WireUroGen Appoints Chris Degnan as Chief Financial OfficerNASDAQ:URGNUroGen Pharma Ltd
02/10/202422:00Business WireFirst Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNASDAQ:URGNUroGen Pharma Ltd
25/09/202406:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
 Showing the most relevant articles for your search:NASDAQ:URGN

Your Recent History

Delayed Upgrade Clock